New Amsterdam Pharma
Bob Rambo has over 30 years of experience in the biopharmaceutical industry. Bob began their career in 1987 as a Research Assistant at Penn State University. In 1989, they joined Merck as a Professional Sales Representative and worked their way up to become the Global Brand Leader of the MK-7110 COVID-19 Therapeutics, Global Brand Leader of the Hepatitis/Hepatology and NASH Franchise, Global Marketing Director of the Hepatitis C Franchise, and Global Team Leader of Academic Professional Engagement. In 2021, they joined RJR Consulting Group, LLC as a Principal and is currently the Executive Vice President of Marketing and Medical Affairs at NewAmsterdam Pharma.
Bob Rambo received their MBA in Marketing from the Fox School of Business at Temple University between 1990 and 1993. Bob also earned their BS in Microbiology from Penn State University between 1983 and 1987.
This person is not in any offices
New Amsterdam Pharma
1 followers
Founded in 2019 by the venture capital firm Forbion and John Kastelein, NewAmsterdam Pharma is a privately held, clinical-stage company focused on the research and development of transformative therapies for cardiometabolic diseases. Its mission is to improve patient care in populations where traditional therapies are not tolerated or have been unsuccessful.